PCI Pharma Services has congratulated Vertex Pharmaceuticals and Mannkind Corporation for their recent awards in the Healthcare Compliance Packaging Council’s (HCPC) 2015 Compliance Package of the Year competition
HCPC recognised Vertex as the overall winner for the Orkambi package while also naming MannKind’s Afrezza as second runner up.
Orkambi is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have two copies of the F508del mutation in their CFTR gene.
Submitted by PCI on behalf of Vertex, Orkambi is provided in daily blister units, with graphics highlighting the AM and PM dosing requirements.
Individual blister units are file-packed into a weekly organiser carton, with individual days neatly arranged to illustrate the daily regimen.
Dosing instructions are positioned to educate the patient, reminding patients to take the AM and PM doses 12 hours apart and to take their medicine with fat-containing foods.
Four weekly packs are provided in an outer monthly carton, which contains graphics that further reinforce dosing instructions as well as the FDA-approved labelling.
Prescription Afrezza, a rapid-acting inhaled insulin breathed through the patient’s lungs, is used to control high blood sugar in adults with type 1 and type 2 diabetes.
Submitted by PCI on behalf of MannKind, Afrezza is provided to patients delivered in colour-coded prefilled cartridges.
Individual cartridges are blister-packed in quantities of 15 based on a colour-coding system to indicate the strength. Indication of the strength of each cartridge is also molded in the plastic of the individual cartridge.
Two 15-count cartridge blisters are provided in an overwrapped pouch. The pouched unit reinforces the colour-coding methodology by using the drug strength colours in the package graphics, in addition to providing detailed instructions for refrigeration of the product.
The carton artwork provides dosing instructions, a colour-coded dosing chart based on the number of units needed per dose, as well as a calendar to guide the patient for the timely replacement of the disposable inhaler unit.